Keyword: The Bill & Melinda Gates Foundation
The goal is to start testing in vivo gene-based treatments for the diseases in humans within 10 years.
Lyndra will use the funds to create a once-monthly pill that delivers a continuous dose of the hormones estrogen and progestin.
Raj Krishnan discusses building Biological Dynamics, isolation methods for diagnostic testing and more.
As we near the end of the year, we take a look back over the biggest stories of 2018 and gauge what readers found the most interesting.
Two years after its founding, Biomatics Capital Partners has raised $300 million for its second fund and signed on two new venture partners.
The Gates Medical Research Institute will turn drug industry expertise on diseases that kill millions annually in low- and middle-income countries.
The extension puts Visterra back on the multifront path through the clinic it plotted out before its aborted IPO attempt.
The Bill & Melinda Gates Foundation is investing up to $40 million spur research into the use of TCR-based therapeutics to treat tuberculosis and HIV.
Lundbeck chief Schultz will lead Teva, former CDC director Frieden leads a new health project, Roivant named Eisai exec Waxman as general counsel.
Vir Biotechnology focuses on developing vaccines and drugs to cure infectious diseases for which there are currently scarce treatments. Though it hasn’t provided any details about its pipeline quite yet, its launch was remarkable for the sheer size of the funding: $150 million from ARCH Venture Partners.